Trillium Therapeutics Appoints Dr. Ingmar Bruns as Chief Medical Officer
November 02 2020 - 4:15PM
Trillium Therapeutics Inc.
(“Trillium”
or the
“Company”)
(NASDAQ/TSX: TRIL), a clinical stage
immuno-oncology company developing innovative therapies for the
treatment of cancer, today announced the appointment of Ingmar
Bruns, M.D., Ph.D. as Chief Medical Officer, effective immediately.
Dr. Bruns will succeed Dr. Yaping Shou, who has elected to resign
to pursue new opportunities. Dr. Shou will remain with the Company,
in a consulting position, to assist with the transition.
“We are extremely pleased to welcome Ingmar to
our management team. His strong operational and strategic
leadership will be instrumental in shaping Trillium’s future
clinical development strategy and execution,” said Jan Skvarka,
Chief Executive Officer of Trillium. “His expertise in patient
care as well as translational and clinical research positions him
greatly to advance our multiple phase 2 programs expected to start
next year.”
Dr. Bruns brings more than 17 years of
experience in hematology and oncology as a physician and scientist.
Over the past three years, Dr. Bruns served as the Senior Vice
President and Head of Clinical Development at Pieris
Pharmaceuticals, a clinical stage biotechnology company, where he
built and led the clinical development organization. From 2013
through 2017, Dr. Bruns led clinical development of several high
priority oncology assets at Bayer Pharmaceuticals. Before his
industry tenure, Dr. Bruns served as an attending hematologist and
oncologist as well as a physician-scientist at Albert Einstein
College of Medicine in New York, and previously the University
Hospital of Dusseldorf in Germany. Dr. Bruns has authored over 50
publications in the field of hematology and oncology, including
several lead authorships in high impact journals such as Nature
Medicine, Blood and Leukemia. He received his M.D. and Ph.D. from
the University of Lubeck in Germany.
“I am excited to join the outstanding Trillium
team and look forward to contributing to the advancement of
Trillium’s differentiated clinical-stage CD47-targeting programs,”
said Dr. Bruns. “Trillium’s programs represent potentially
transformative therapeutic options via blockade of an innate immune
checkpoint for patients with hematological malignancies as well as
solid tumors.”
Said Dr. Shou: “Together with the excellent
Trillium team and clinical investigators, it has been my pleasure
to guide development of both anti-CD47 programs during the past 2.5
years. Both compounds hold great promise for patients and I look
forward to their continued successful clinical development.”
“I would like to thank Dr. Shou for her critical
contributions to our clinical development, in particular for
positioning us strongly for the next stage of our clinical
development efforts. We wish her all the best in her future
endeavors,” added Dr. Skvarka.
About Trillium
Therapeutics
Trillium is an immuno-oncology company
developing innovative therapies for the treatment of cancer. The
company’s two clinical programs, TTI-621 and TTI-622, target
CD47, a “don’t eat me” signal that cancer cells frequently use to
evade the immune system.
For more information visit:
www.trilliumtherapeutics.com
Caution Regarding Forward-Looking
Information
This press release contains forward-looking
statements within the meaning of applicable United States
securities laws and forward-looking information within the meaning
of Canadian securities laws (collectively, “forward-looking
statements”). Forward-looking statements in this press release
include statements about, without limitation, our plans for
initiating and advancing multiple phase 2 studies next year. With
respect to the forward-looking statements contained in this press
release, Trillium has made numerous assumptions regarding, among
other things: the impact of the COVID-19 pandemic on its
operations, the effectiveness and timeliness of preclinical and
clinical trials; and the completeness, accuracy and usefulness of
the data. While Trillium considers these assumptions to be
reasonable, these assumptions are inherently subject to significant
scientific, business, economic, competitive, market and social
uncertainties and contingencies. Additionally, there are known and
unknown risk factors that could cause Trillium’s actual results,
performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by
the forward-looking statements contained in this press release. A
discussion of risks and uncertainties facing Trillium appears in
Trillium’s Annual Information Form for the year ended December 31,
2019 filed with Canadian securities authorities and on Form 40-F
with the U.S. Securities Exchange Commission, each as updated by
Trillium’s continuous disclosure filings, which are available at
www.sedar.com and at www.sec.gov. All forward-looking
statements herein are qualified in their entirety by this
cautionary statement, and Trillium disclaims any obligation to
revise or update any such forward-looking statements or to publicly
announce the result of any revisions to any of the forward-looking
statements contained herein to reflect future results, events or
developments, except as required by law.
Investor Relations:James
ParsonsChief Financial OfficerTrillium Therapeutics Inc.
416-595-0627 x232james@trilliumtherapeutics.com
www.trilliumtherapeutics.com
Media Relations:Mike BeyerSam Brown
Inc.312-961-2502mikebeyer@sambrown.com
Trillium Therapeutics (NASDAQ:TRIL)
Historical Stock Chart
From Jul 2024 to Aug 2024
Trillium Therapeutics (NASDAQ:TRIL)
Historical Stock Chart
From Aug 2023 to Aug 2024